WO2006012642A3 - Pyrrole derivatives as pharmaceutical agents - Google Patents

Pyrrole derivatives as pharmaceutical agents Download PDF

Info

Publication number
WO2006012642A3
WO2006012642A3 PCT/US2005/026916 US2005026916W WO2006012642A3 WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3 US 2005026916 W US2005026916 W US 2005026916W WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agents
pyrrole derivatives
receptors
activity
modulating
Prior art date
Application number
PCT/US2005/026916
Other languages
French (fr)
Other versions
WO2006012642A2 (en
Inventor
Bannen Lynne Canne
Jeff Chen
Lisa Esther Dalrymple
Brenton T Flatt
Timothy Patrick Forsyth
Xiao-Hu Gu
Morrison B Mac
Grace Mann
Larry W Mann
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens Jr
Tie-Lin Wang
Yong Wang
Jason H Wu
Original Assignee
Bannen Lynne Canne
Jeff Chen
Lisa Esther Dalrymple
Exelixis Inc
Brenton T Flatt
Timothy Patrick Forsyth
Xiao-Hu Gu
Morrison B Mac
Grace Mann
Larry W Mann
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens Jr
Tie-Lin Wang
Yong Wang
Jason H Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US59246904P priority Critical
Priority to US59243904P priority
Priority to US60/592,439 priority
Priority to US60/592,469 priority
Application filed by Bannen Lynne Canne, Jeff Chen, Lisa Esther Dalrymple, Exelixis Inc, Brenton T Flatt, Timothy Patrick Forsyth, Xiao-Hu Gu, Morrison B Mac, Grace Mann, Larry W Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C Stevens Jr, Tie-Lin Wang, Yong Wang, Jason H Wu filed Critical Bannen Lynne Canne
Priority claimed from CN 200580026842 external-priority patent/CN101006052B/en
Publication of WO2006012642A2 publication Critical patent/WO2006012642A2/en
Publication of WO2006012642A3 publication Critical patent/WO2006012642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
PCT/US2005/026916 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents WO2006012642A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US59246904P true 2004-07-30 2004-07-30
US59243904P true 2004-07-30 2004-07-30
US60/592,439 2004-07-30
US60/592,469 2004-07-30

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
CN 200580026842 CN101006052B (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
EP05803281.4A EP1773768B8 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
KR20077004302A KR101155288B1 (en) 2004-07-30 2005-07-30 Pyrrole Derivatives as Pharmaceutical Agents
PL05803281T PL1773768T3 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
CA2573426A CA2573426C (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
RU2007107388/04A RU2470916C2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as medicinal substances
US11/572,962 US8026237B2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
NZ55263205A NZ552632A (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
BRPI0513677-6A BRPI0513677A (en) 2004-07-30 2005-07-30 pyrrol derivatives with pharmaceutical agents
ES05803281T ES2697524T3 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
SI200532237T SI1773768T1 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
DK05803281.4T DK1773768T3 (en) 2004-07-30 2005-07-30 Pyrrold derivatives as pharmaceutical agents
JP2007523832A JP4703649B2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
LTEP05803281.4T LT1773768T (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
AU2005266890A AU2005266890C1 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
IL180630A IL180630A (en) 2004-07-30 2007-01-10 Pyrrole derivatives as pharmaceutical agents
NO20070910A NO20070910L (en) 2004-07-30 2007-02-16 Pyrrole as a pharmaceutical
US13/214,665 US8367667B2 (en) 2004-07-30 2011-08-22 Pyrrole derivatives as pharmaceutical agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/214,665 Division US8367667B2 (en) 2004-07-30 2011-08-22 Pyrrole derivatives as pharmaceutical agents

Publications (2)

Publication Number Publication Date
WO2006012642A2 WO2006012642A2 (en) 2006-02-02
WO2006012642A3 true WO2006012642A3 (en) 2006-07-27

Family

ID=35786783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026916 WO2006012642A2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents

Country Status (19)

Country Link
US (2) US8026237B2 (en)
EP (1) EP1773768B8 (en)
JP (2) JP4703649B2 (en)
KR (1) KR101155288B1 (en)
AU (1) AU2005266890C1 (en)
BR (1) BRPI0513677A (en)
CA (1) CA2573426C (en)
DK (1) DK1773768T3 (en)
ES (1) ES2697524T3 (en)
HU (1) HUE041596T2 (en)
IL (1) IL180630A (en)
LT (1) LT1773768T (en)
NO (1) NO20070910L (en)
NZ (1) NZ552632A (en)
PL (1) PL1773768T3 (en)
RU (1) RU2470916C2 (en)
SG (1) SG155188A1 (en)
SI (1) SI1773768T1 (en)
WO (1) WO2006012642A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
AT545644T (en) 2004-09-24 2012-03-15 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and applications thereof
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, Compositions containing them, the preparation thereof and uses thereof
DE10354060A1 (en) * 2003-11-19 2005-06-02 Merck Patent Gmbh pyrrole
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
DK1773768T3 (en) * 2004-07-30 2018-11-26 Exelixis Inc Pyrrold derivatives as pharmaceutical agents
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496206B1 (en) 2005-01-05 2015-02-27 애브비 인코포레이티드 Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN101142172A (en) 2005-01-05 2008-03-12 艾博特公司 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006076202A1 (en) * 2005-01-10 2006-07-20 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
RS20090208A (en) 2006-10-31 2010-06-30 Pfizer Products Inc. Pyrazoline compounds as mineralocorticoid receptor antagonists
JP5363312B2 (en) * 2007-04-09 2013-12-11 第一三共株式会社 Atropisomers of pyrrole derivatives
WO2009023272A1 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
JP5736098B2 (en) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド Pharmaceutical composition for treating central nervous system disorders
JP2010536871A (en) * 2007-08-22 2010-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Pyrrole compound having sphingosine-1-phosphate receptor agonist or antagonist biological activity
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8389567B2 (en) * 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2011516488A (en) * 2008-03-31 2011-05-26 テバ ファーマシューティカル インダストリーズ リミティド Method for preparing sunitinib and its salts
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
DK2315591T3 (en) 2008-08-15 2016-06-06 Nivalis Therapeutics Inc NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents
DK2315590T3 (en) 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrole inhibitors of S-nitrosoglutathione reductase
EP2318007B1 (en) 2008-08-15 2013-01-23 N30 Pharmaceuticals, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
CN102256969A (en) * 2008-08-27 2011-11-23 钙医学公司 Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2349997B1 (en) * 2008-10-08 2015-08-12 Exelixis, Inc. Atropisomers of (hydroxyalkyl) pyrrole derivatives
EP2349996B1 (en) 2008-10-08 2014-01-01 Exelixis, Inc. 1-phenylpyrrole compounds
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2010107476A1 (en) * 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
AU2010245072B2 (en) * 2009-05-05 2013-11-28 Merck Sharp & Dohme Corp. p38 kinase inhibiting agents
EP2253617A1 (en) * 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
EP2470183B1 (en) * 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2477982A4 (en) * 2009-09-16 2013-04-03 Calcimedica Inc Compounds that modulate intracellular calcium
UY33200A (en) * 2010-01-26 2011-08-31 Sanofi Aventis Derivatives 3-heteroaroylamino-oxygen substituted propionic acid and their use as pharmaceuticals
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
JP6180930B2 (en) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and compositions for stimulating reepithelialization during wound healing processes
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
KR20190007106A (en) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
JP2016514693A (en) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Hybrid necrotosis inhibitor
ES2640063T3 (en) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and their use as medicines for the treatment of hepatitis B
CN105164105B (en) 2013-04-10 2018-01-30 第一三共株式会社 Crystallization of azole derivatives and preparation method thereof
JP6441315B2 (en) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー Sulfamoylthiophenamide derivatives and their use as pharmaceuticals for treating hepatitis B
JP6422868B2 (en) 2013-07-23 2018-11-14 第一三共株式会社 Medicine for prevention or treatment of hypertension
HUE039152T2 (en) 2013-07-25 2018-12-28 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105473552B (en) 2013-08-27 2017-11-10 第一三共株式会社 Method for producing azole derivatives and its intermediate
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN107530350A (en) 2014-12-11 2018-01-02 哈佛理事会 Inhibitor of cellular necrosis and correlation technique
CN107205984A (en) * 2015-01-26 2017-09-26 第三共株式会社 Solid composition of pyrrole carboxamide
WO2017164208A1 (en) 2016-03-24 2017-09-28 第一三共株式会社 Medicine for treating renal disease
EP3525778A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
US20190262340A1 (en) 2016-10-11 2019-08-29 Bayer Pharama Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
WO2018153898A1 (en) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selective partial adenosine a1 receptor agonists in combination with mineralocorticoid receptor antagonists
DE102017008472A1 (en) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Combination containing PDE5 inhibitors and mineralocorticoid receptor antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators
US20040267028A1 (en) * 2001-09-24 2004-12-30 Smith Roger A Preparation and use of pyrrole derivatives for treating obesity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0341497B2 (en) * 1979-06-28 1991-06-24
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JPH07116139B2 (en) 1986-06-09 1995-12-13 三菱化学株式会社 Manufacturing method of lactams
DE3717068A1 (en) * 1987-05-21 1988-12-08 Basf Ag 4-substituted-10-cyanomethylene-pyrrolo (4,3-e) benzo-azepine
JPH04145078A (en) * 1990-10-04 1992-05-19 Hokko Chem Ind Co Ltd Pyrroledicarboxylic acid derivative and herbicide
JPH10251258A (en) * 1997-03-14 1998-09-22 Suntory Ltd Pyrroloazepine-based compound
DE19719585A1 (en) * 1997-05-09 1998-11-12 Hoechst Ag New N-sulphonyl-di:amino:carboxylic acid derivatives
DE69925250T2 (en) * 1998-01-14 2006-02-23 Nippon Shinyaku Co., Ltd. Activators of the potassium-channels
AU2960599A (en) * 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
GB9817548D0 (en) * 1998-08-12 1998-10-07 Novartis Ag Organic compounds
WO2000027823A1 (en) * 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
DE60017115T2 (en) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amide derivatives and medical use
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1406660B1 (en) * 2001-07-19 2007-06-06 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
DE60131967D1 (en) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4 nuclear receptor binding compounds
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag Nr1h4 nuclear receptor binding compounds
DE10148328A1 (en) 2001-09-29 2003-04-10 Bayerische Motoren Werke Ag A method for positioning a motor vehicle steering wheel
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
EP1545515A1 (en) * 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
EP1398029A1 (en) * 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
CN1485072A (en) 2002-09-28 2004-03-31 李大鹏 Coix seed oil soft capsule for curing prostate diseases and the application thereof
US20040102511A1 (en) * 2002-11-21 2004-05-27 Jitendra Sattigeri Substituted pyrrole derivatives
KR100674769B1 (en) * 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 Novel cb 1 receptor inverse agonists
CN101012193A (en) * 2003-01-02 2007-08-08 霍夫曼-拉罗奇有限公司 Novel CB 1 receptour inverse agonists
DK1773768T3 (en) * 2004-07-30 2018-11-26 Exelixis Inc Pyrrold derivatives as pharmaceutical agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040267028A1 (en) * 2001-09-24 2004-12-30 Smith Roger A Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1773768A4 *

Also Published As

Publication number Publication date
LT1773768T (en) 2018-11-26
EP1773768B8 (en) 2018-12-26
RU2007107388A (en) 2008-09-10
US8367667B2 (en) 2013-02-05
NO20070910L (en) 2007-04-26
US20110301128A1 (en) 2011-12-08
SG155188A1 (en) 2009-09-30
AU2005266890B2 (en) 2011-10-06
NZ552632A (en) 2010-11-26
US8026237B2 (en) 2011-09-27
IL180630D0 (en) 2007-06-03
JP2010077166A (en) 2010-04-08
DK1773768T3 (en) 2018-11-26
WO2006012642A2 (en) 2006-02-02
AU2005266890C1 (en) 2014-09-25
SI1773768T1 (en) 2018-12-31
AU2005266890A1 (en) 2006-02-02
RU2470916C2 (en) 2012-12-27
JP4703649B2 (en) 2011-06-15
HUE041596T2 (en) 2019-05-28
US20080234270A1 (en) 2008-09-25
CA2573426C (en) 2015-11-17
KR20070045283A (en) 2007-05-02
AU2005266890B9 (en) 2014-05-08
KR101155288B1 (en) 2012-07-02
ES2697524T3 (en) 2019-01-24
PL1773768T3 (en) 2019-03-29
EP1773768A4 (en) 2008-08-06
IL180630A (en) 2013-08-29
EP1773768B1 (en) 2018-08-22
CA2573426A1 (en) 2006-02-02
JP2008508308A (en) 2008-03-21
BRPI0513677A (en) 2007-11-27
EP1773768A2 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
EP2526934A3 (en) Inhibitors of bruton's tyrosine kinase
MX2007009429A (en) Pyrrolopyrimidines useful as inhibitors of protein kinase.
MX2007004936A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity.
HK1161873A1 (en) Spiro oxindole compounds and their uses as therapeutic agents
TW200533663A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
CR8497A (en) Azepinoindol derivatives as pharmaceutical agents
WO2007056221A3 (en) Aminopyrimidines useful as kinase inhibitors
CR9875A (en) Dipeptidyl peptidase inhibitors to treat diabetes
CA2533701A1 (en) Oligomeric compounds and compositions for use in modulation of small non-coding rnas
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
SA2822B1 (en) Pyrimidine Derivatives as Modulators of Toll-Like Receptor Activity
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2008051805A3 (en) Triazolo-pyridazine protein kinase modulators
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
PL216049B1 (en) Urea derivatives, compositions containing urea derivatives as well as the application of urea derivatives in the production of medications used to treat systolic heart failure
MX2009006704A (en) New compounds.
IL177717D0 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
SI1846406T1 (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

WWE Wipo information: entry into national phase

Ref document number: 2573426

Country of ref document: CA

Ref document number: 180630

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200700352

Country of ref document: ZA

Ref document number: 2005266890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 552632

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005803281

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 605/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12007500256

Country of ref document: PH

Ref document number: 1200700186

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001201

Country of ref document: MX

Ref document number: 2007523832

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2005266890

Country of ref document: AU

Date of ref document: 20050730

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200580026842.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005266890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077004302

Country of ref document: KR

Ref document number: 07018563

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2007107388

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005803281

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0513677

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 11572962

Country of ref document: US